Miami Cancer Institute – Multispecialty Grand Rounds Evaluation - March 8, 2021

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

As a result of attending this conference, to what extent do you agree that you will be better able to: (rate the objectives) *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	N/A
Assess whether prophylactic nodal radiation is appropriate for the treatment of high-risk neuroblastoma.	Assess whether prophylactic nodal radiation is appropriate for the treatment of high-risk neuroblastoma. - 5	Assess whether prophylactic nodal radiation is appropriate for the treatment of high-risk neuroblastoma. - 4	Assess whether prophylactic nodal radiation is appropriate for the treatment of high-risk neuroblastoma. - 3	Assess whether prophylactic nodal radiation is appropriate for the treatment of high-risk neuroblastoma. - 2	Assess whether prophylactic nodal radiation is appropriate for the treatment of high-risk neuroblastoma. - 1	Assess whether prophylactic nodal radiation is appropriate for the treatment of high-risk neuroblastoma. - N/A
Identify whether a radiotherapy boost is appropriate for the treatment of high-risk neuroblastoma.	Identify whether a radiotherapy boost is appropriate for the treatment of high-risk neuroblastoma. - 5	Identify whether a radiotherapy boost is appropriate for the treatment of high-risk neuroblastoma. - 4	Identify whether a radiotherapy boost is appropriate for the treatment of high-risk neuroblastoma. - 3	Identify whether a radiotherapy boost is appropriate for the treatment of high-risk neuroblastoma. - 2	Identify whether a radiotherapy boost is appropriate for the treatment of high-risk neuroblastoma. - 1	Identify whether a radiotherapy boost is appropriate for the treatment of high-risk neuroblastoma. - N/A
Implement and understand the role of 131I-MIBG therapy for the treatment of high-risk neuroblastoma and which agents does data indicate should be combined with 131I-MIBG.	Implement and understand the role of 131I-MIBG therapy for the treatment of high-risk neuroblastoma and which agents does data indicate should be combined with 131I-MIBG. - 5	Implement and understand the role of 131I-MIBG therapy for the treatment of high-risk neuroblastoma and which agents does data indicate should be combined with 131I-MIBG. - 4	Implement and understand the role of 131I-MIBG therapy for the treatment of high-risk neuroblastoma and which agents does data indicate should be combined with 131I-MIBG. - 3	Implement and understand the role of 131I-MIBG therapy for the treatment of high-risk neuroblastoma and which agents does data indicate should be combined with 131I-MIBG. - 2	Implement and understand the role of 131I-MIBG therapy for the treatment of high-risk neuroblastoma and which agents does data indicate should be combined with 131I-MIBG. - 1	Implement and understand the role of 131I-MIBG therapy for the treatment of high-risk neuroblastoma and which agents does data indicate should be combined with 131I-MIBG. - N/A

How satisfied or dissatisfied were you with the following conference content? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Lecture materials.	Lecture materials. - 5	Lecture materials. - 4	Lecture materials. - 3	Lecture materials. - 2	Lecture materials. - 1
Speaker's effectiveness in addressing the learning objectives.	Speaker's effectiveness in addressing the learning objectives. - 5	Speaker's effectiveness in addressing the learning objectives. - 4	Speaker's effectiveness in addressing the learning objectives. - 3	Speaker's effectiveness in addressing the learning objectives. - 2	Speaker's effectiveness in addressing the learning objectives. - 1

Was this course fair, balanced and without commercial bias? *

Yes

If you checked "No,” please explain why: *

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

Name

Leave this field blank

You are here

Miami Cancer Institute – Multispecialty Grand Rounds Evaluation - March 8, 2021